EudraCT Number: 2004-000326-70 Sponsor Protocol Number: R076477-SCH-302/702 Start Date: 2004-08-11
Sponsor Name: Janssen-Cilag, Johnson & Johnson spol. s.r.o.
Full Title: A Randomized, 6-Week Double-Blind, Placebo-Controlled Study With an Optional 24-Week Open-Label Extension to Evaluate the Safety and Tolerability of Flexible Doses of Extended Release OROS® Paliper...
Medical condition: Schizophrenia
Disease: Version SOC Term Classification Code Term Level
Population Age: Elderly Gender: Male, Female
Trial protocol: CZ (Completed)
Trial results: View results

EudraCT Number: 2004-000327-15 Sponsor Protocol Number: XL119-001 Start Date: 2004-11-25
Sponsor Name: Exelixis, Inc.
Full Title: A Phase 3 Multicenter, Single-Blind, Randomized Study of XL119 Versus 5-Fluorouracil (5-FU) plus Leucovorin (LV) in Subjects with Advanced Bilary Tumors Not Amenable to Coventional Surgery
Medical condition: Advanced Bilary Tract Tumours: Gall bladder cancer and Cholangiocarcinoma
Disease: Version SOC Term Classification Code Term Level
7.0 10028982 LLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: ES (Ongoing) GB (Prematurely Ended) BE (Completed) IT (Prematurely Ended)
Trial results: View results
EudraCT Number: 2004-001117-34 Sponsor Protocol Number: APL-B-013-02 Start Date: 2004-10-13
Sponsor Name: Pharma Mar S.A.
Full Title: A Phase II Multicenter,Open-Label, Clinical And Pharmacokinetic Study Of Aplidin® As A 1-Hour Weekly IV Infusion, In Patients With Relapsed Or Refractory aggressive non-Hodgkin’s Lymphoma.
Medical condition: Aggressive non-Hodgkin’s Lymphoma.For aggressive NHL patient cure is still the target of therapy and a CR is a prerequisite to achieve this goal. Salvage therapy needs more aggressive experimental ...
Disease: Version SOC Term Classification Code Term Level
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: ES (Ongoing) IT (Completed)
Trial results: View results

EudraCT Number: 2004-001125-20 Sponsor Protocol Number: FIRM-ACT Start Date: 2004-07-26
Sponsor Name: AZIENDA OSPEDALIERA S. LUIGI GONZAGA
Full Title: First International Randomized trial in Metastatic Adrenocortical Cancer Treatment FIRM-ACT Etoposide, Doxorubicin, Cisplatin and Mitotane vs. Streptozotocin and Mitotane
Medical condition: Chemotherapy in patients with locally advanced or metastatic adrenocortical cancer in adults and children
Disease: Version SOC Term Classification Code Term Level
6.1 10001378 HLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: IT (Completed)
Trial results: (No results available)
EudraCT Number: 2004-001823-39 Sponsor Protocol Number: 103502 Start Date: 2004-11-15
Sponsor Name: GlaxoSmithKline Biologicals
Full Title: An open, randomized, controlled, phase II study to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals’ 11-valent pneumococcal conjugate vaccine, when administered intramuscularly...
Medical condition: Prophylactic vaccination against pneumococcal diseases in infants and diseases caused by Neisseria meningitidis C.
Disease: Version SOC Term Classification Code Term Level
Population Age: Infants and toddlers, Under 18 Gender: Male, Female
Trial protocol: SE (Completed)
Trial results: View results

EudraCT Number: 2004-000751-42 Sponsor Protocol Number: D1441C00150 Start Date: 2006-04-07
Sponsor Name: AstraZeneca AB
Full Title: A 26-week, International, Multicenter, Open-label Phase IIIb Study of the Safety and Tolerability of Quetiapine Fumarate (SEROQUEL™) Immediate-release Tablets in Daily Doses of 400 mg to 800 mg in ...
Medical condition: SCHIZOPHRENIA or BIPOLAR I DISORDER
Disease: Version SOC Term Classification Code Term Level
Population Age: Children, Adolescents, Under 18 Gender: Male, Female
Trial protocol: DE (Completed)
Trial results: View results
EudraCT Number: 2004-000773-60 Sponsor Protocol Number: SNMC 301 Start Date: 2004-10-22
Sponsor Name: Healthcare & Pharma Consulting AG (Europe)
Full Title: 52 week multicenter, randomized, double-blind placebo-controlled trial evaluating the efficacy and safety of SNMC in patients with chronic hepatitis C
Medical condition: Chronic hepatitis C
Disease: Version SOC Term Classification Code Term Level
Population Age: Adults Gender: Male, Female
Trial protocol: LV (Completed)
Trial results: (No results available)

EudraCT Number: 2004-000632-82 Sponsor Protocol Number: AC-052-333 Start Date: 2004-09-16
Sponsor Name: Actelion Pharmaceuticals Ltd.
Full Title: Long term bosentan open label extension of the RAPIDS-2 study in Systemic Sclerosis patients with ischemic digital ulcers
Medical condition: SSc is a multi-system disorder of unknown etiology characterized by fibrosis and vascular obliteration in the skin and visceral organs. The pathogenesis of SSc involves immunologic mechanisms vascu...
Disease: Version SOC Term Classification Code Term Level
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: GB (Completed) IT (Completed)
Trial results: View results
EudraCT Number: 2004-002802-31 Sponsor Protocol Number: PENT-IBD-CH CZ Start Date: 2005-01-25
Sponsor Name: Ferring-Leciva, a.s.
Full Title: Multicentre, Controlled, Randomised, Open, Cross-over Study Comparing the Acceptability of Pentasa® Sachets versus Pentasa® tbl. 500mg in Children with Crohn´s Disease
Medical condition: children patients with the Crohn s disease in any stage (where mesalazine treatment is appropriate)
Disease: Version SOC Term Classification Code Term Level
Population Age: Children, Adolescents, Under 18 Gender: Male, Female
Trial protocol: CZ (Ongoing)
Trial results: View results

EudraCT Number: 2004-002803-34 Sponsor Protocol Number: Cetcapox-RT_31.08.2004 Start Date: 2004-12-23
Sponsor Name: Klinik und Poliklinik fuer Strahlentherapie, Universität Erlangen-Nürnberg
Full Title: Phase I/II-Studie Praeoperative Radiochemotherapie mit Capecitabin plus Oxaliplatin und Cetuximab beim lokal fortgeschrittenen Rektumkarzinom im UICC-Stadium II und III
Medical condition: Rektumkarzinom
Disease: Version SOC Term Classification Code Term Level
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: DE (Completed)
Trial results: (No results available)